Cathryn Rankin

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Charles D. Blanke, Cathryn Rankin, George D. Demetri et al. · Journal of Clinical Oncology · 2008 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +13

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

Michael C. Heinrich, Kouros Owzar, Christopher L. Corless et al. · Journal of Clinical Oncology · 2008 · 653 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials

Piotr Rutkowski, M. van Glabbeke, Cathryn Rankin et al. · Journal of Clinical Oncology · 2010 · 401 citations · Full text

Medicine, Dermatology, Oncology +13

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts)

M. M. Van Glabbeke, Kouros Owzar, Cathryn Rankin et al. · Journal of Clinical Oncology · 2007 · 383 citations

Medicine, Oncology, Pharmacology +10

Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study

Linda L. Garland, Cathryn Rankin, David R. Gandara et al. · Journal of Clinical Oncology · 2007 · 222 citations · Full text

Medicine, Oncology, Pharmacology +17